Silexion Therapeutics Corp

Silexion Therapeutics Corp shareholders approved an increase in the company's authorized share capital by 10,000,000 ordinary shares, raising the total from 5,900,000 to 15,900,000 ordinary shares. This amendment became effective on July 21, 2026. Additionally, shareholders approved the exercisability of 399,020 Series C and D ordinary warrants and 13,966 placement agent warrants, which were issued as part of an induced warrant exercise transaction in May 2026. Both proposals were approved at the reconvened extraordinary general meeting on July 20, 2026.

Silexion Therapeutics Corp. is holding an extraordinary general meeting on July 13, 2026, to seek shareholder approval for two key proposals. The first is the exercisability of new warrants and placement agent warrants issued in a May 18, 2026, transaction that helped restore Nasdaq listing compliance. The second proposal seeks to increase the authorized share capital by 10,000,000 ordinary shares to support ongoing operations, clinical trials for its SIL-204 product candidate, and potential business development. The board unanimously recommends shareholders vote in favor of both proposals.

Silexion Therapeutics Corp completed a 1-for-10 reverse share split, effective after the close of trading on May 28, 2026. The company's ordinary shares began trading on a split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol "SLXN" at market open on May 29, 2026. Concurrently, the company issued a notice to warrant holders, adjusting the number of shares issuable upon exercise and increasing the exercise price proportionally to $15,525.00 per post-Reverse Share Split ordinary share.

Silexion Therapeutics Corp. announced a 1-for-10 reverse share split of its ordinary shares, effective after market close on May 28, 2026. Trading on a split-adjusted basis will commence on May 29, 2026, under the existing ticker symbol "SLXN." The par value will increase from $0.0135 to $0.135 per share, with no fractional shares issued. This strategic move is intended to maintain Nasdaq listing compliance, strengthen the capital structure, reduce volatility, and improve flexibility for future financings as the company approaches a Phase 2/3 trial for SIL204.

Silexion Therapeutics Corp filed an amendment to its 10-K report to correct a typographical error in the date of its management's evaluation of internal control over financial reporting. The correct evaluation date is December 31, 2025, not December 31, 2024. The company's management, including the CEO and CFO, concluded that both disclosure controls and procedures and internal control over financial reporting were effective as of December 31, 2025.

Silexion Therapeutics announced its first quarter 2026 financial results and provided a business update. The company received approval from the Israeli Ministry of Health to initiate its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer and subsequently submitted a Clinical Trial Application to Germany. Financially, Silexion reported a net loss of $2.7 million for Q1 2026, an increase from the prior year, driven by higher R&D and G&A expenses related to clinical trial preparations. The company also undertook capital-raising actions to support its clinical development and maintain Nasdaq listing compliance.

Silexion Therapeutics announced significant progress in its clinical development, receiving Israeli Ministry of Health approval and submitting a Clinical Trial Application to Germany for its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, with trial initiation expected in Q2 2026. Financially, the company reported increased R&D and G&A expenses, leading to a net loss of $2.7 million in Q1 2026. However, subsequent to quarter-end, Silexion strengthened its balance sheet through a warrant exercise and ATM facility, restoring compliance with Nasdaq listing requirements.

Silexion Therapeutics Corp reported a net loss of $2.73 million for the first quarter of 2026, an increase from $1.74 million in the prior year. The company's cash and cash equivalents significantly decreased to $2.41 million as of March 31, 2026, from $5.99 million at the end of 2025. Management has concluded there is substantial doubt about the company's ability to continue as a going concern, as current funds are expected to last only several months. Operating expenses notably increased across R&D and G&A categories.

Silexion Therapeutics Corp entered an inducement offer letter agreement with certain warrant holders. This agreement facilitates the exercise of 1,995,092 existing warrants at a reduced price of $0.50 per share, expected to generate approximately $1.0 million in gross proceeds. In consideration, the company will issue new Series C and Series D warrants to purchase up to 3,990,184 ordinary shares, also at an exercise price of $0.50 per share. The net proceeds will be used for general corporate purposes.

Silexion Therapeutics Corp. announced it has entered into definitive agreements for the immediate exercise of certain outstanding warrants, expecting to generate approximately $1 million in gross proceeds. The exercise involves 1,995,092 ordinary shares at a reduced price of $0.50 per share. In consideration, the company will issue new unregistered Series C and Series D warrants, totaling nearly 4 million shares, also with an exercise price of $0.50 per share, exercisable upon shareholder approval. The net proceeds will be used for general corporate purposes and working capital.